AM1241 is a selective cannabinoid CB2 receptor agonist used for its analgesic effects in inflammatory pain models, including carrageenan-induced thermal hyperalgesia and mechanical allodynia; it inhibits spinal Fos protein expression (a neuronal activity marker) in inflammatory conditions; it demonstrates dose-dependent antinociceptive activity without causing hypothermia, catalepsy, CNS-mediated behavioral impairment, or reduced locomotor activity typically associated with non-selective cannabinoid agonists; its analgesic effects are mediated specifically through CB2 receptors, as confirmed by blockade with selective CB2 antagonists (e.g., AM630 and SR144528) but not CB1 antagonists.